Publications & Presentations

Check out our scientific presentations to learn more about our ongoing drug development programs.

Program

November 2022

Preclinical Activity and Safety Profile of JANX007, a Novel PSMA-Targeting Tumor-Activated T Cell Engager for Treatment of Metastatic Castration-Resistant Prostate Cancer

Thomas R. DiRaimondo et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 2022

Preclinical Development of an EGFR-Targeted Tumor-Activated T Cell Engager (JANX008) with Enhanced Safety to Activity Multiple and Pharmacokinetics Profile

Thomas R. DiRaimondo et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting

May 2022

Preclinical Activity and Safety Profile of JANX007, a Novel PSMA-Targeting Tumor-Activated T Cell Engager for Treatment of Metastatic Castration-Resistant Prostate Cancer

Thomas R. DiRaimondo et al. Protein & Antibody Engineering Summit (PEGS) Boston Conference

May 2022

Preclinical Development of an EGFR-Targeted Tumor-Activated T Cell Engager (JANX008) with Enhanced Safety to Activity Multiple and Pharmacokinetics Profile

Thomas R. DiRaimondo et al. Protein & Antibody Engineering Summit (PEGS) Boston Conference

Our current development programs are focused on selectively modulating T cells to fight cancer and autoimmune diseases.

Learn About Our Founding Technology